Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

LB Pharmaceuticals Inc LBRX

Set alert

Price alert · LBRX

All alert types
39.04 USD -0.66 -1.66%

At close

39.50 +0.46 +1.18%

Pre-market · Nov 3, 5:37 AM ET

Bid
39.04 × 1
Ask
39.10 × 1
38.24 Day range 40.91
14.32 52-week range 50.16
YTD
+75.38%
1 year
+141.43%
Open
40.56
Prev close
39.70
Mkt cap
1.26B
Vol
466.45K
Avg vol
361.92K
EPS
0.10
P/E
390.40
Div yield
0.00%
More statistics
Low
38.24
High
40.91
Forward P/E
-7.26
Beta
0.00
Short ratio
12.64
Inst. own
102.44%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
41.38
200-d avg
32.57
1y target
58.00

MAX chart

Chart tools
Interval
1m5m15m30m

Chart is warming up

The all-time price history for LBRX has not been loaded yet. Try again in a moment.

Financial health

Altman Z-Score

25.27 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

2 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

FMP rating

C+2 / 5 overall

  • DCF 3
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 4
  • P/E 1
  • P/B 2

Valuation

P/E -22.3×
FY 2022: -4.3×FY 2023: -9.8×FY 2024: -1.0×FY 2025: -22.3×
FY 2022 5y median -7.0× FY 2025
P/S 0.0×
FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 1.9×
FY 2022: -2.1×FY 2023: -1.8×FY 2024: -0.6×FY 2025: 1.9×
FY 2022 5y median -1.2× FY 2025
P/FCF -16.0×
FY 2022: -22.5×FY 2023: -5.1×FY 2024: -1.1×FY 2025: -16.0×
FY 2022 5y median -10.5× FY 2025
EV/EBITDA -12.7×
FY 2022: -5.2×FY 2023: -32.0×FY 2024: -0.7×FY 2025: -12.7×
FY 2022 5y median -9.0× FY 2025
EV/Sales 0.0×
FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -6.3%
FY 2022: -4.5%FY 2023: -19.8%FY 2024: -87.9%FY 2025: -6.3%
FY 2022 5y median -13.0% FY 2025

Profitability

Gross Margin 0.0%
FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -8.4%
FY 2022: 49.8%FY 2023: 18.2%FY 2024: 66.7%FY 2025: -8.4%
FY 2022 5y median 34.0% FY 2025
ROIC -9.9%
FY 2022: -13.4%FY 2023: -26.4%FY 2024: -250.2%FY 2025: -9.9%
FY 2022 5y median -19.9% FY 2025
ROA -8.1%
FY 2022: -66.8%FY 2023: -13.7%FY 2024: -188.2%FY 2025: -8.1%
FY 2022 5y median -40.3% FY 2025

Growth (YoY)

Revenue 0.0%
FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2022 FY 2025
Operating Income 53.1%
FY 2022: 0.0%FY 2023: -305.0%FY 2024: -469.9%FY 2025: 53.1%
FY 2022 FY 2025
EPS (diluted) 94.4%
FY 2022: 0.0%FY 2023: 56.3%FY 2024: -907.3%FY 2025: 94.4%
FY 2022 FY 2025
Free Cash Flow 34.5%
FY 2022: 0.0%FY 2023: -344.2%FY 2024: -344.1%FY 2025: 34.5%
FY 2022 FY 2025

Financial Health

Current Ratio 41.4×
FY 2022: 45.8×FY 2023: 17.5×FY 2024: 3.6×FY 2025: 41.4×
FY 2022 5y median 29.5× FY 2025
Quick Ratio 41.4×
FY 2022: 45.8×FY 2023: 17.5×FY 2024: 3.6×FY 2025: 41.4×
FY 2022 5y median 29.5× FY 2025
Debt / Equity 0.0×
FY 2022: -0.8×FY 2023: 0.0×FY 2024: -0.0×FY 2025: 0.0×
FY 2022 5y median -0.0× FY 2025
Net Debt / EBITDA 9.9×
FY 2022: -0.2×FY 2023: 10.4×FY 2024: 0.3×FY 2025: 9.9×
FY 2022 5y median 5.1× FY 2025
Interest Coverage 0.0×
FY 2022: -1.3×FY 2023: -2.4×FY 2024: 0.0×FY 2025: 0.0×
FY 2022 5y median -0.7× FY 2025

Dividends

Dividend Yield 0.0%
FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2022 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31